Serogroup B, Electrophoretic Type 15Neisseria meningitidisin Canada | Zendy

Daniel A. Kertesz | Zendy; Michael B. Coulthart | Zendy; J. A. Ryan | Zendy; W M Johnson | Zendy; F. E. Ashton | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Serogroup B, Electrophoretic Type 15Neisseria meningitidisin Canada

Author(s) -

Daniel A. Kertesz,

Michael B. Coulthart,

J. A. Ryan,

W M Johnson,

F. E. Ashton

Publication year - 1998

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/517439

Subject(s) - neisseria meningitidis , meningococcal disease , genotype , virology , neisseriaceae , microbiology and biotechnology , meningococcal vaccine , disease , medicine , biology , antibiotics , bacteria , genetics , gene

Invasive meningococcal disease is nationally reportable in Canada. In recent years, a serogroup C genotype, designated electrophoretic type 15 (ET15), has been the most frequently isolated meningococcal genotype in Canada and has caused epidemics across the country. Between August 1993 and September 1995, there were 9 cases of invasive meningococcal disease caused by a variant of this genotype, expressing group B capsular polysaccharide. The appearance of serogroup B:ET15 was related temporally and geographically to mass immunization campaigns designed to control serogroup C meningococcal disease in Canada. Since there is no vaccine available to control serogroup B meningococcal disease, the appearance of this variant may have public-health significance if it demonstrates the same epidemic potential as its serogroup C counterpart.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research